Archive for the ‘A:Diseases with A’ Category

Finesteride in Treatment of Alopecia (Baldness)

Sunday, July 11th, 2010

If you are suffering from baldness or alopecia, you might have tried many treatment modalities in alternative medicines and could not get desired results, than it is high time you try modern medicine. Modern medicine can offer some remedy to baldness or alopecia. USFDA (United States Food and Drug Administration) has approved use of finesteride (Propecia) for treatment of alopecia or baldness in males.

Finesteride, marketed as Propecia, Proscar etc. is used for treatment of alopecia. Finesteride is a 5-alpha reductase enzyme inhibitor drug. 5-alpha reductase enzyme is responsible for conversion of testosterone to dihydrotestosterone (DHT) and by blocking 5-alpha reductase enzyme finesteride blocks the conversion of testosterone into dihydrotestosterone, which is more powerful androgen than testosterone. Due to lower level of powerful dihydrotestosterone, the androgenic activity in the scalp is reduced. By reducing androgenic activity in the scalp, finesteride helps in preventing hair fall and also helps in regrowing of hairs.

Studies have shown that men (approximately 2 out of 3 who takes finesteride 1 mg daily) with mild to moderate hair loss can get hairs regrow, as seen by increased hair count. Finesteride can also prevent fall of hairs. If a patient is taking finesteride for treatment of baldness (alopecia), if there is no increase in number of hairs (or regrowth of hairs) at least the hair fall can be prevented.

Side effects of finesteride:

Finesteride has several side effects, some of which are potentially serious. Side effects of finesteride include impotence, ejaculation disturbance, abnormal sexual performance, erectile dysfunction, gynecomastia (breast development in males), pain in testicles etc. The side effects generally disappear in those who discontinue the treatment with finesteride and also in most of the patients over time who continue to take finesteride despite side effects.

Finesteride is not recommended in females for treatment of baldness as it is not effective in treating baldness in females. Finesteride should be avoided during pregnancy and those women planning pregnancy.

Prevention of Anthrax

Monday, April 13th, 2009

Prevention of anthrax with vaccine is successful and vaccination is recommended if you are at risk of developing anthrax. Prevention of anthrax is required in risky population because if untreated anthrax is almost 100% fatal for inhalational anthrax and more than 20% fatal for cutaneous anthrax. Inhalational anthrax is the form most likely to be responsible for death in a setting of a bioterrorist attack. Patients with inhalational anthrax are not contagious and do not require special isolation.

The first successful anthrax vaccine was developed by Louis Pasteur in 1881 for animals. At present anthrax vaccine is produced from the cell-free culture supernatant of an attenuated, nonencapsulated strain of B. anthracis (known as anthrax vaccine adsorbed or AVA) and is licensed for human use.

As an alternative to AVA, clinical trials for safety in humans and efficacy in animals are currently under way to evaluate the role of recombinant protective antigen of B. anthracis toxins. In preventing the development of clinical disease and death in a post-exposure setting in non-human primates a 2 week trial course of AVA + ciprofloxacin was found to be superior to ciprofloxacin alone.

Chemoprophylaxis: The current recommendation for postexposure prophylaxis is 60 days of antibiotics (Ciprofloxacin or doxycycline); it would be better to include immunization with anthrax vaccine (AVA) if available. There is a potential for B. anthracis to engineer and express penicillin resistance, and due to that, the empirical regimen of antibiotics of choice in this setting is either ciprofloxacin or doxycycline.

The prevention of bioterrorist attacks is the responsibility of the Govt. and not discussed here. But support of the general public is must for the Govt. to prevent bioterrorist attacks successfully.  

Treatment of Anthrax: the Killer Disease

Sunday, April 12th, 2009

Anthrax can be easily and successfully treated if diagnosed promptly and treatment instituted early and immediately after diagnosis. Anthrax is in the news because of the recent microbial bioterrorist attacks in the United States. Modern science has revealed methods and unleashed a devil of deliberately spreading anthrax and other diseases in ways not appreciated by our ancestors. The combination of basic scientific research, good medical practice, and constant vigil will be required by the public and the Govt. to defend against such attacks.

Clinical features of anthrax: the clinical feature depends on the route of entry of the organism mainly gastrointestinal, cutaneous, and inhalational. Symptoms include cutaneous lesions of papule to eschar (begins as a papule following the introduction of spores through an opening in the skin. This papule then evolves to a painless vesicle followed by the development of a coal-black, necrotic eschar). If the anthrax is due to inhalation the symptoms are fever, malaise, chest pain, abdominal discomfort etc. On chest x-ray there is pleural effusion and widened mediastinum.

Diagnosis of anthrax: Anthrax is diagnosed with laboratory tests like PCR (polymerase chain reaction) test, Wright stain of blood peripheral smear, Gram staining and blood culture of the organism causing anthrax (Bacillus anthracis a gram-positive, nonmotile, spore-forming rod that is found in soil and predominantly causes disease in herbivores like cattle, goats, and sheep).

Treatment of anthrax: penicillin (amoxicillin), ciprofloxacin, and doxycycline are the currently licensed antibiotics for treatment of anthrax. But clindamycin and rifampin can also used as part of treatment regimens and they are also being used to treat anthrax. Treatment is started with penicillin (amoxicillin), ciprofloxacin, and doxycycline till sensitivity results are known and once sensitivity results are known treatment is changed if required.

Post exposure treatment: It is done with Ciprofloxacin, 500 mg, orally twice a day for 60 days or doxycycline 100 mg orally twice a day for 60 days or amoxicillin (likely to be effective if strain penicillin sensitive) 500 mg, orally thrice a day for 60 days.

Treatment of active anthrax: Ciprofloxacin, 500 mg intravenously 12 hourly or doxycycline 100 mg intravenously 12 hourly plus Clindamycin, 900 mg IV 8 hourly and/or rifampin, 300 mg IV 12 hourly. Switch to oral route when stable for 60 days total treatment including intravenous route.  

Anaplasmosis: HumanGranulocytotropicAnaplasmosis

Thursday, October 9th, 2008

Human Granulocytotropic Anaplasmosis (HGA) is caused by A. phagocytophilum. In 2006 more than 3257 cases of HGA were reported to the CDC, Atlanta. The distribution of cases is similar to that for Lyme disease because of the shared Ixodes scapularis tick vector. Most of the cases were reported from upper midwestern and northeastern United States. White-tailed deer & white footed mice in the United States and red deer in Europe are natural reservoirs.

Signs and symptoms: The incubation period of Human Granulocytotropic Anaplasmosis is 4-8 days. After the incubation period the following symptoms like fever, malaise, myalgia (muscle pain) and headache appear. Some patients may develop nausea, vomiting, confusion and rash.

Severe complications like adult respiratory distress syndrome (ARDS), a toxic shock syndrome, and opportunistic infections, which may be life-threatening, can develop. Case fatality rate is very less about 0.5% and up to 7% patients may require intensive care.

Diagnosis: PCR testing of blood from patients with active disease before initiation of therapy is sensitive and specific. Other non specific findings like thrombocytopenia, leukopenia, or elevation in serum alanine or aspartate aminotransferase are seen.

Treatment: Doxycycline 100 mg orally twice daily is the drug of choice for treatment of HGA. Rifampin can be used successfully in children and pregnant women. Most of the patients respond within 24 to 48 hours.